Vitamin B12 (Cobalamin): A Comprehensive Reference
1. Identity, Chemical Nature, and Nomenclature
Vitamin B12 is a water-soluble vitamin that is naturally present in some foods, added to others, and available as a dietary supplement and a prescription medication. Because vitamin B12 contains the mineral cobalt, compounds with vitamin B12 activity are collectively called cobalamins. Cobalamin is the general term used to describe a group of cobalt-containing compounds (corrinoids) that have a particular structure containing the sugar ribose, phosphate, and a base (5,6-dimethyl benzimidazole) attached to the corrin ring.
Cobalamin consists of four compounds with different biological functions, although these molecules are chemically similar. Cobalamin is a tetrapyrrolic corrin ring with a central cobalt moiety. The molecular formula for the core cobalamin structure — including the cyanocobalamin form — is C₆₃H₈₈N₁₄O₁₄PCo.
1.1 Principal Forms
Vitamin B12 exists in several forms: methylcobalamin (MeCbl), adenosylcobalamin (AdoCbl), hydroxycobalamin (OHCbl), and cyanocobalamin (CNCbl).
- Methylcobalamin (MeCbl) and 5′-deoxyadenosylcobalamin (AdoCbl): these are the metabolically active forms of vitamin B12.
- Cyanocobalamin (CNCbl): the most common form used in dietary supplements and food fortification because cyanide stabilizes the molecule against degradation. Bacterial fermentation creates AdoB12 and MeB12, which are converted to cyanocobalamin by the addition of potassium cyanide in the presence of sodium nitrite and heat; once consumed, cyanocobalamin is converted to the biologically active AdoB12 and MeB12.
- Hydroxocobalamin (OHCbl): this form, along with cyanocobalamin, becomes biologically active after conversion to methylcobalamin or 5-deoxyadenosylcobalamin. Hydroxocobalamin can be injected intramuscularly to treat vitamin B12 deficiency.
The most common form of vitamin B12 in dietary supplements is cyanocobalamin. Other forms of vitamin B12 in supplements are adenosylcobalamin, methylcobalamin, and hydroxycobalamin. No evidence indicates that absorption rates of vitamin B12 in supplements vary by form of the vitamin.
There is a growing body of research demonstrating lower tissue retention, higher urinary excretion, and consequently lower overall bioavailability of vitamin B12 supplemented in the form of CNCbl, compared to OHCbl, MeCbl, and AdoCbl. Additionally, some researchers suggest the use of natural vitamin B12 forms instead of CNCbl for long-term supplementation to avoid the accumulation of cyanide in human tissues, which is especially important for smokers, as tobacco smoke is one of the major sources of cyanide. However, existing evidence does not suggest any differences among forms with respect to absorption or bioavailability under standard conditions in healthy individuals.
2. Natural Sources
Vitamin B12 is present in foods of animal origin, including fish, meat, poultry, eggs, and dairy products. Plant foods do not naturally contain vitamin B12. However, fortified breakfast cereals and fortified nutritional yeasts are readily available sources of vitamin B12 that have high bioavailability.
Since only bacteria and some archaea possess the genes and enzymes necessary to synthesize vitamin B12, plant and algae sources all obtain the vitamin secondarily from symbiosis with various species of bacteria, or in the case of fermented plant foods, from bacterial fermentation. Natural plant and algae sources include fermented plant foods such as tempeh and seaweed-derived foods such as nori and laverbread. Methylcobalamin has been identified in Chlorella vulgaris.
The body's ability to absorb vitamin B12 from dietary supplements is largely limited by the capacity of intrinsic factor. For example, only about 10 mcg of a 500 mcg oral supplement is actually absorbed in healthy people.
3. Historical and Traditional Use
The discovery of vitamin B12, the elucidation of its role in metabolism, and the effects and treatment of its deficiency occurred in distinct phases over more than 100 years, and it was the subject of two separate Nobel Prizes.
Clinical reports and studies of patients with pernicious anemia throughout the 19th century resulted in enough clinical definition to allow Minot and Murphy to put together the first hallmark study on treatment of the condition, leading them to a Nobel Prize. The discovery of a treatment for pernicious anemia (PA), a fatal disease until 1926, earned Minot and Murphy a Nobel Prize.
Previously, pernicious anemia had been an incurable condition, but these workers had found that sufferers could survive if they would eat large quantities of raw liver each day, with the hope that this could soon be replaced by more potent liver extracts. These researchers were not the first to suggest that an inadequacy of nutrients was the cause of pernicious anemia, but their particular input was a carefully designed intervention in well-characterized pernicious anemia patients consuming a special diet containing large amounts of liver. They found consistent improvement in the clinical and blood status of all subjects, most of whom remained in remission indefinitely.
After the successful intervention studies, the next advance was made by Castle, who discovered that a gastric component, which he called intrinsic factor, was missing in pernicious anemia. Many years later, intrinsic factor was found to be a glycoprotein that formed a complex with vitamin B12, promoting its absorption through ileal receptors.
The extrinsic factor was finally purified from liver and isolated as crystals in 1948 by both Karl August Folkers and his team at Merck, and Ernest Lester Smith and his team at Glaxo, who published their papers within weeks of each other. The extrinsic factor was named vitamin B12, and was later renamed cobalamin. The vitamin was isolated by two groups simultaneously and was crystallized and characterized in the laboratory of Dorothy Hodgkin, contributing to her Nobel Prize in 1964.
After the essential liver factor (cobalamin, or vitamin B12) had finally been isolated in 1948, it became clear that even healthy people needed this factor but that they absorbed it efficiently so that a normal mixed diet was sufficient.
4. Key Constituents and Mechanisms of Action
4.1 Enzymatic Cofactor Roles
Vitamin B12 is required for proper red blood cell formation, neurological function, and DNA synthesis.
Vitamin B12 functions as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase. Methionine synthase catalyzes the conversion of homocysteine to methionine. Cobalamin in the form of adenosylcobalamin acts as a cofactor for the enzyme methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA.
Methylcobalamin serves as a cofactor in the conversion of homocysteine to methionine in the body. Furthermore, in the form of adenosylcobalamin, the vitamin is crucial in converting methylmalonyl-coenzyme A (CoA) to succinyl-CoA. Both of these reactions are essential for cell division and growth.
4.2 Neurological Function
Vitamin B12 is required for the development, myelination, and function of the central nervous system; healthy red blood cell formation; and DNA synthesis. Adenosylcobalamin and methylcobalamin have biological activity to act as cofactors in enzymatic reactions that play a role in the synthesis of DNA, myelin, and fatty acids, which are vital for cell division and growth.
4.3 Homocysteine Metabolism and Methylation
Vitamin B12 is involved in the breakdown of a protein called homocysteine. High homocysteine levels are associated with an increased risk of heart disease and stroke as it may promote the formation of blood clots and excess free radical cells, and may impair normal blood vessel function. A lack of adequate vitamin B12 can increase homocysteine levels.
4.4 Absorption Physiology
Vitamin B12 is bound to protein in food and must be released before it is absorbed. The process starts in the mouth when food is mixed with saliva. The freed vitamin B12 then binds with haptocorrin, a cobalamin-binding protein in the saliva. More vitamin B12 is released from its food matrix by the activity of hydrochloric acid and gastric protease in the stomach, where it binds to haptocorrin. In the duodenum, digestive enzymes free the vitamin B12 from haptocorrin, and this freed vitamin B12 combines with intrinsic factor, a transport and delivery binding protein secreted by the stomach's parietal cells. The resulting complex is absorbed in the distal ileum by receptor-mediated endocytosis.
If vitamin B12 is added to fortified foods and dietary supplements, it is already in free form and therefore does not require the separation step.
The estimated bioavailability of vitamin B12 from food varies by vitamin B12 dose because absorption decreases drastically when the capacity of intrinsic factor is exceeded (at 1–2 mcg of vitamin B12).
5. Recommended Intakes and Dosage
The Recommended Dietary Allowance (RDA) for vitamin B12 is based on the amount needed for the maintenance of hematological status and normal serum vitamin B12 values. An assumed absorption of 50 percent is included in the recommended intake. The RDA for adults is 2.4 μg/day of vitamin B12.
The RDA for men and women ages 14 years and older is 2.4 micrograms (mcg) daily. For pregnancy and lactation, the amount increases to 2.6 mcg and 2.8 mcg daily, respectively.
The full schedule of RDAs across age groups is: Birth to 6 months, 0.4 mcg (AI); 7–12 months, 0.5 mcg (AI); 1–3 years, 0.9 mcg; 4–8 years, 1.2 mcg; 9–13 years, 1.8 mcg; 14–18 years, 2.4 mcg; 19+ years, 2.4 mcg; Pregnancy, 2.6 mcg; Lactation, 2.8 mcg.
There is not sufficient scientific evidence to set a Tolerable Upper Intake Level (UL) for vitamin B12 at this time. No upper limit has been set for vitamin B12, as there is no established toxic level. However, some evidence suggests that supplements of 25 mcg per day or higher may increase the risk of bone fractures.
Only about 10 mcg of a 500 mcg oral supplement is actually absorbed in healthy people. Two studies used 1,000 μg/day oral vitamin B12 and showed no relevant difference to intramuscularly applied vitamin B12 with regard to vitamin B12 blood levels. One trial used 2,000 μg/day vitamin B12 and showed higher vitamin B12 blood levels in favour of oral vitamin B12.
6. Forms and Routes of Administration
Vitamin B12 is available in multiple preparations:
- Oral tablets and capsules: The most common form; in dietary supplements, vitamin B12 is usually present as cyanocobalamin, a form that the body readily converts to the active forms methylcobalamin and 5-deoxyadenosylcobalamin.
- Sublingual tablets and lozenges: In addition to oral dietary supplements, vitamin B12 is available in sublingual preparations as tablets or lozenges. These preparations are frequently marketed as having superior bioavailability, although evidence suggests no difference in efficacy.
- Intramuscular (IM) injection: A prescription form of vitamin B12 can be given as a shot, usually used to treat vitamin B12 deficiency.
- Nasal gel/spray: Vitamin B12 is also available as a prescription nasal gel spray. This formulation appears to be effective in raising vitamin B12 blood levels in adults and children. A small clinical study with 10 participants (mean age 81 years) found that the bioavailability of a 1,000 mcg cobalamin dose was 2% with intranasal administration, which is similar to the bioavailability of an oral dose.
6.1 Oral versus Intramuscular Administration
Sixteen studies comprising a total of 6,098 participants were included in one 2025 systematic review and meta-analysis. Vitamin B12 supplementation was associated with a significant increase in serum cobalamin levels across all routes of administration (pooled mean difference = +402.6 pg/mL; 95% CI: 293.6 to 511.5; p < 0.001). Homocysteine levels were also significantly reduced across all groups (pooled mean difference = −4.83 μmol/L; 95% CI: −6.55 to −3.11; p < 0.001). The findings indicate that all three administration routes effectively increase serum B12 levels, with no statistically significant differences among them.
7. Body Systems and Health Areas
7.1 Hematological System: Megaloblastic Anemia
If cobalamin is not present in sufficient amount, megaloblastic anemia occurs by inhibiting DNA synthesis due to the folate trap. Megaloblastic (pernicious) anemia was the condition whose historical connection to vitamin B12 drove the entire discovery of the nutrient. Vitamin B12, also known as the anti-pernicious anemia factor, is an essential micronutrient totally dependent on dietary sources.
The evidence base for the role of vitamin B12 in treating megaloblastic anemia is well-established, supported by decades of clinical observation. Deficiency causes abnormally large, immature red blood cells that cannot function normally. Correction of deficiency—whether through oral high-dose supplementation or intramuscular injection—reliably reverses the hematological abnormalities.
7.2 Neurological System: Subacute Combined Degeneration and Peripheral Neuropathy
Subacute combined degeneration (SCD) is a neurological disorder primarily caused by vitamin B12 deficiency. This condition leads to progressive demyelination and axonal damage, predominantly affecting the dorsal and lateral columns of the spinal cord.
Early symptoms often include paresthesia and sensory loss with numbness, tingling sensations in the hands or feet, gait ataxia, and muscle weakness in the legs. Approximately up to 30% of patients with vitamin B12 deficiency experience peripheral neuropathy, which may occur alongside SCD, resulting in myeloneuropathy characterized by both upper and lower motor neuron signs. Persistent vitamin B12 deficiency can lead to cognitive decline and, less frequently, to autonomic and optic neuropathy.
In 1991, Healton et al. performed detailed neurologic evaluations of 143 patients with vitamin B12 deficiency; 74% presented with neurologic symptoms. Isolated numbness or paresthesias were present in 33%. Gait abnormalities occurred in 12%. Psychiatric or cognitive symptoms were noted in 3%.
Hematologic and neurologic manifestations are occasionally dissociated. An inverse correlation in the severity of both manifestations has been suggested. In patients with neuropsychiatric abnormalities, 28% lack anemia or macrocytosis.
7.3 Cardiovascular System: Homocysteine Lowering
Epidemiological studies have shown that higher blood homocysteine levels appear to be associated with higher risks of coronary, cerebral, and peripheral vascular disease and are inversely related to blood levels of folate and of vitamin B12. However, observational studies cannot exclude the possibility that elevated homocysteine levels may be associated with some other factor, rather than being causally related to vascular disease.
After standardization for a pretreatment homocysteine concentration of 12 μmol/L and folate concentration of 12 nmol/L, dietary folic acid reduced homocysteine levels by 25% (95% CI: 23 to 28%) with similar effects in a daily dosage range of 0.5 to 5 mg. Vitamin B12 (mean 0.5 mg) produced an additional reduction in blood homocysteine of 7%.
A 2023 meta-analysis including a total of 21 RCTs (N = 1,625 participants) found that homocysteine levels were significantly lower after B12 supplementation compared with the control group (pooled weighted mean difference, −4.15 μmol/L; 95% confidence interval, −4.86, −3.45; P < 0.001).
The evidence proved that vitamin B supplementation effectively reduces homocysteine levels and the risk of stroke and vascular deaths. However, no risk reduction was observed for cardiovascular events among the vitamin group. This distinction is important: while B12 consistently lowers homocysteine as a biomarker, translation to reduced hard cardiovascular endpoints has not been demonstrated robustly across large-scale RCTs. The evidence for cardiovascular benefit beyond homocysteine lowering remains inconclusive.
7.4 Cognitive Function and Dementia
Vitamin B12 levels in the subclinical low-normal range (<250 pmol/L) are associated with Alzheimer's disease, vascular dementia, and Parkinson's disease. Vegetarianism and metformin use contribute to depressed vitamin B12 levels and may independently increase the risk for cognitive impairment.
A systematic review concluded that there was insufficient evidence to show a clear link between serum vitamin B12 concentrations and cognitive decline or dementia in older adults. More specifically, five of eight studies reported no association between serum vitamin B12 and the development of dementia. Five of eight studies reported no association between holotranscobalamin or serum vitamin B12 alone or in combination with low serum folate concentrations and the development of Alzheimer's disease.
Two randomized controlled trials and 6 cohort studies showed no association or inconsistent associations between vitamin B12 intake and cognitive function. Random-effects meta-analysis showed that serum/plasma vitamin B12 (50 pmol/L) was not associated with risk of dementia (4 cohort studies), global cognition z scores (4 cohort studies), or memory z scores (4 cohort studies).
Low serum vitamin B12 levels are associated with neurodegenerative disease and cognitive impairment. There is a small subset of dementias that are reversible with vitamin B12 therapy and this treatment is inexpensive and safe. Vitamin B12 therapy does not improve cognition in patients without pre-existing deficiency. There is a need for large, well-resourced clinical trials to close the gaps in our current understanding of the nature of the associations of vitamin B12 insufficiency and neurodegenerative disease.
Vitamin B12 supplementation has been shown to improve biomarker levels, particularly MMA and homocysteine, though cognitive benefits are dependent on the timing of intervention. Clinical trials have demonstrated that individuals with mild cognitive impairment who receive B12 therapy experience slower cognitive decline, whereas those with advanced dementia do not show significant improvement. This underscores the importance of early diagnosis and timely intervention in preventing long-term neurological deterioration.
While observational studies have linked low serum B12 levels to cognitive decline, RCT evidence suggests that supplementation does not necessarily translate into functional improvements. One possible explanation is the presence of irreversible neuronal damage by the time B12 deficiency is detected biochemically, especially in the absence of anemia or symptoms.
7.5 Pregnancy and Fetal Development
Having a vitamin B12 deficiency (B12 levels below 148 mol/L) or low vitamin B12 has been associated with preterm delivery. Low B12 concentrations in human milk occur commonly in two situations involving inadequate intake: when the mother is a strict vegetarian and in developing countries where the usual consumption of animal products is low.
A 2023 community-based, double-blind, randomized, placebo-controlled trial in Nepal found that supplementation improved vitamin B12 status, but it had no effect on infant neurodevelopment and growth. The researchers therefore concluded that there is no evidence to support routine vitamin B12 supplementation during pregnancy. This finding applies specifically to populations that are not broadly deficient; the benefit of correcting frank deficiency during pregnancy remains a distinct clinical situation with strong observational support.
7.6 Depression and Mental Health
A 2020 review of 35 studies revealed no evidence showing positive effects of vitamin B12 on depressive symptoms. However, researchers wrote that lower levels of vitamin B12 in the body were linked to a higher risk for developing depression, and therefore concluded that early vitamin B12 supplementation can delay depression onset and improve the effect of antidepressants. Other research is less clear. A 2021 systematic review, meta-analysis and meta-regression of 16 randomized controlled trials also found no evidence that vitamin B12 supplements had any effect on cognitive function outcomes or measures of depression for patients without established deficiency. The overall evidence in this domain is preliminary and mixed.
8. Populations at Risk for Deficiency
8.1 Older Adults
Because 10 to 30 percent of people older than 50 years are estimated to have atrophic gastritis with low stomach acid secretion, they may have decreased bioavailability of B12 from food. Many older adults, especially those with atrophic gastritis, have trouble absorbing vitamin B12, so people over 50 should get most of their vitamin B12 from fortified foods and/or dietary supplements. These forms are more easily absorbed than the vitamin B12 in food.
8.2 Vegans and Strict Vegetarians
People who follow a vegetarian or vegan diet can sometimes have low levels. This is because plant foods don't have vitamin B12. Therefore, people who follow vegan diets need to obtain vitamin B12 from either fortified foods, such as many breakfast cereals and fortified nutritional yeasts, or dietary supplements.
8.3 Pernicious Anemia
The most common cause of subacute combined degeneration is pernicious anemia. It is defined by the presence of antibodies against the parietal cells of the stomach which produce intrinsic factor, resulting in insufficient absorption of vitamin B12. In pernicious anemia, oral supplementation at very high doses (taking advantage of passive absorption) or parenteral administration is required.
9. Safety Considerations and Drug Interactions
9.1 General Safety
There is not sufficient scientific evidence to set a Tolerable Upper Intake Level (UL) for vitamin B12 at this time. The body gets rid of the excess B12 that it doesn't absorb through either stool or urine. That's why it is very difficult to get high B12 levels just from what you eat.
9.2 Metformin Interaction
Long-term metformin use is known to cause clinical vitamin B12 deficiency with the predominant mechanism being due to calcium-mediated reduction in intestinal absorption. It is seen more commonly in elderly vegetarians. Long-term use of metformin has been associated with vitamin B12 deficiency in about 6–30% of its users. Among its adverse effects, vitamin B12 deficiency is of particular concern, especially with long-term use, where prevalence may reach up to 50%.
Positive safety signals were detected for both metformin and all proton pump inhibitors individually. Patients on metformin–pantoprazole combination therapy experienced significantly higher rates of hospitalization and life-threatening events compared to those on pantoprazole alone. These findings suggest that patients receiving metformin and PPIs together, particularly the elderly, may face a higher risk of serious vitamin B12 deficiency-related complications.
9.3 Proton Pump Inhibitors and H2-Receptor Antagonists
Vitamin B12 is released from its food matrix by the activity of hydrochloric acid and gastric protease in the stomach. Drugs that reduce gastric acid output therefore impair this initial release step. Studies have confirmed that both proton pump inhibitors (PPIs) and histamine H2-receptor antagonists are associated with reduced vitamin B12 absorption from food, with the degree of risk correlating with dose and duration of use (reported in JAMA 2013;310:2435-42).
9.4 Nitrous Oxide
Subacute combined degeneration of the spinal cord, a hallmark of B12 deficiency, presents with symptoms like numbness, weakness, and gait disturbances. In addition to B12 deficiency related to dietary causes, neurological complications can also arise from malabsorption conditions, such as pernicious anemia or prolonged nitrous oxide exposure. Nitrous oxide irreversibly oxidizes the cobalt atom in cobalamin, inactivating both methylcobalamin-dependent and adenosylcobalamin-dependent enzyme systems. This represents an acute and severe pharmacological interaction.
9.5 Considerations for Smokers
Some researchers suggest the use of natural vitamin B12 forms instead of cyanocobalamin for long-term supplementation to avoid the accumulation of cyanide in human tissues, which is especially important for smokers, as tobacco smoke is one of the major sources of cyanide.
9.6 High-Dose Supplement Considerations
Some evidence suggests that supplements of 25 mcg per day or higher may increase the risk of bone fractures. Additionally, persistently elevated serum vitamin B12 has been associated with certain underlying conditions, such as hepatic disease and myeloproliferative disorders, though high B12 from supplementation alone in healthy individuals has not been shown to cause direct harm.
10. Diagnostic Markers of Status
To accurately diagnose and assess the impact of B12 deficiency on brain function, multiple biomarkers are used, including serum vitamin B12, holotranscobalamin (holoTC), methylmalonic acid (MMA), and total homocysteine (tHcy). These all serve as indirect indicators of vitamin B12 status, offering insights into metabolic dysregulations that contribute to neurological impairments. Although dose-response evidence on sensitive markers of vitamin B12 status (methylmalonic acid and holotranscobalamin) was scarce, 4 of 5 cohort studies reported significant associations with risk of dementia, Alzheimer's disease, or global cognition.
11. Summary of Evidence Strength by Area
- Megaloblastic/pernicious anemia treatment: Strong, well-established evidence from many decades of clinical use; vitamin B12 supplementation reliably reverses hematological abnormalities when deficiency is the cause.
- Neurological deficits from deficiency (SCD, peripheral neuropathy): Strong evidence that deficiency causes these conditions and that early treatment prevents or reverses them; less evidence that supplementation in non-deficient populations provides neurological benefit.
- Homocysteine lowering: Consistent and robust evidence from RCTs that B12 supplementation (especially combined with folate) reduces homocysteine levels, though translation to reduced cardiovascular events has not been demonstrated.
- Cognitive function and dementia prevention: Evidence is weak to mixed. Observational associations between low B12 and cognitive decline exist, but RCT data do not support supplementation improving cognition in non-deficient individuals. A small subset of dementias driven by frank deficiency may be reversible with supplementation.
- Pregnancy and fetal outcomes: Strong evidence supports maintaining adequate B12 during pregnancy; evidence does not support routine high-dose supplementation beyond correcting deficiency in populations with adequate baseline status.
- Depression: Preliminary and mixed; no high-quality RCT evidence supports B12 supplementation for depression in non-deficient individuals.
References
Go back